Asfand Yar Cheema/LinkedIn
Sep 4, 2025, 22:00
Asfand Yar Cheema at SOHO 2025: PSM Cohort Study on GLP-1 Agonist Therapy Key Clinical Outcomes for Polycythemia Vera
MPN Hub shared on X:
”CONGRESS | SOHO 2025 | PRESENTATION
Asfand Yar Cheema, Cleveland Clinic
Presents results from a PSM cohort study evaluating the association of GLP-1 agonist therapy and key clinical outcomes in Polycythemia Vera.
GLP-1 agonist therapy is associated with significantly reduced risks of all-cause mortality, myelofibrosis progression, VTE, healthcare utilization, AKI, and ischemic stroke/TIA.
Randomized controlled trials are required to confirm GLP-1 agonist safety and efficacy in PV.
Follow our live feed for more updates.”
Find more slides in the gallery.
All on Hemostasis and Thrombosis from SOHO 2025 featured in Hemostasis Today.
-
Jan 22, 2026, 15:36We Must Roll Up Our Sleeves And Help: José Antonio García Erce on Plasma Donation
-
Jan 22, 2026, 15:25Nita Radhakrishnan on Challenges In Congenital Afibrinogenemia
-
Jan 22, 2026, 15:10Jin Q Gives a Summary of 2025’s Most Impactful Cell and Gene Therapy Milestones
-
Jan 22, 2026, 14:57Nirav Dhanesha on CD14 Acting As A Functional Driver of DVT
-
Jan 22, 2026, 11:41Jamilla Goedegebuur and Colleagues on VTE Management in Case of PAD
-
Jan 22, 2026, 11:28Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
-
Jan 22, 2026, 11:19Bruno Odisio: Ablation Margins Are Software-Dependent
-
Jan 22, 2026, 10:38Pedro Perez: The VTE Market Is Clearly Entering Its Next Phase
-
Jan 22, 2026, 10:29Marvin Garcia Reyes Presents a Case of Aorto-Visceral and Aorto-Iliac Thrombosis